All Stories

Sanofi-backed Abcuro raises $200M series C to fund pivotal trial of KLRG1 antibody

Sanofi-backed Abcuro has secured $200 million in series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle disease trial ahead of a planned push to regulators.

Feb 12, 2025 - 14:38
 0
Sanofi-backed Abcuro raises $200M series C to fund pivotal trial of KLRG1 antibody
Sanofi-backed Abcuro has secured $200 million in series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle disease trial ahead of a planned push to regulators.
Read More

Tags:

Previous Article

Aluminum tariffs may push Coca-Cola to use more PET packaging

Next Article

Roll out digital € considering peoples’ concerns: EU Parliament to ECB

Related Posts

Journey of Voyager's ALS gene therapy to clinic hindered by need to find alternative payload

Journey of Voyager's ALS gene therapy to clinic hindere...

Feb 12, 2025  0

Fierce Biotech Layoff Tracker 2025: Encoded trims 29% of team; Inventiva halves staff

Fierce Biotech Layoff Tracker 2025: Encoded trims 29% o...

Feb 13, 2025  0

'Tough but necessary decisions': Frontier Medicines lays off staff to streamline operations

'Tough but necessary decisions': Frontier Medicines lay...

Feb 9, 2025  0